| 2024-12-12 |
复牌提示：
2024-12-11 19:50:00 停牌，复牌日期 2024-12-13 00:00:01
|
| 2024-12-12 |
详情>>
内部人交易：
LALANDE KEVIN M.等共交易12笔
|
| 2024-11-07 |
详情>>
股本变动：
变动后总股本864.86万股
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.11美元,归母净利润-2545.9万美元,同比去年增长-3.59%
|
| 2024-08-02 |
详情>>
业绩披露：
2024年中报每股收益-2.22美元,归母净利润-1799.2万美元,同比去年增长-10.54%
|
| 2024-08-01 |
财报披露：
美东时间 2024-08-01 盘后发布财报
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-1.29美元,归母净利润-1044.1万美元,同比去年增长-42.13%
|
| 2024-04-12 |
股东大会：
将于2024-05-31召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees for director, Chad A. Johnson and Lota S. Zoth, to serve until the 2027 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To select, on a non-binding, advisory basis, the frequency of how often the approval of the compensation of our named executive officers will be presented to our stockholders.
4.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024.
5.To conduct any other business properly brought before the meeting.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-4.18美元,归母净利润-3403.4万美元,同比去年增长-9.57%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.01美元,归母净利润-2457.7万美元,同比去年增长-7.72%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.98美元,归母净利润-1627.7万美元,同比去年增长-4.58%
|
| 2023-05-05 |
详情>>
业绩披露：
2023年一季报每股收益-0.89美元,归母净利润-734.6万美元,同比去年增长4.84%
|
| 2023-03-31 |
股东大会：
将于2023-05-10召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees for director, Richard J. Hawkins and Thomas A. Raffin, to serve until the 2026 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023.
4.To conduct any other business properly brought before the meeting.
|
| 2023-03-07 |
详情>>
业绩披露：
2022年年报每股收益-3.71美元,归母净利润-3106.2万美元,同比去年增长-2.08%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-2.73美元,归母净利润-2281.5万美元,同比去年增长7.96%
|
| 2022-08-10 |
详情>>
业绩披露：
2022年中报每股收益-1.86美元,归母净利润-1556.4万美元,同比去年增长10.04%
|
| 2022-03-23 |
股东大会：
将于2022-05-04召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees for director, An van Es-Johansson, Kevin Lalande and Joseph S. McCracken, to serve until the 2025 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To approve the amended Lumos Pharma, Inc. 2010 Employee Stock Purchase Plan.
4.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
5.To conduct any other business properly brought before the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-06 |
股东大会：
将于2021-05-19召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees for director, Chad A. Johnson and Lota S. Zoth, to serve until the 2024 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
4.To conduct any other business properly brought before the meeting.
|
| 2020-06-23 |
股东大会：
将于2020-07-28召开股东大会
会议内容 ▼▲
- 1.To elect the Board’s nominees for director, Richard J. Hawkins and Thomas A. Raffin, M.D., to serve until the 2023 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
4.To conduct any other business properly brought before the meeting.
|
| 2020-03-19 |
详情>>
拆分方案：
每9.0000合并分成1.0000股
|
| 2019-04-05 |
股东大会：
将于2019-05-09召开股东大会
会议内容 ▼▲
- 1.To elect the Board's nominees for director, Matthew L. Sherman, M.D. and Nicholas N. Vahanian, M.D., to serve until the 2022 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To amend the Company's 2009 Equity Incentive Plan to, among other things, extend the term of the 2009 Equity Incentive Plan.
4.To approve a stock option exchange program, pursuant to which employees and directors may exchange eligible stock options for new stock options with an exercise price equal to the fair market value of the Company’s common stock at the time of the exchange.
5.To approve stock option grants to Chief Executive Officer Charles J. Link, Jr., M.D. and President Nicholas N. Vahanian, M.D.
6.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019.
7.To conduct any other business properly brought before the meeting.
|
| 2018-04-09 |
股东大会：
将于2018-05-23召开股东大会
会议内容 ▼▲
- 1.To elect the nominees for director, Chad A. Johnson, Ernest J. Talarico, III and Lota S. Zoth, nominated by our Board of Directors, to serve until the 2021 Annual Meeting of Stockholders.
2.To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.
3.To indicate, on a non-binding, advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.
4.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.
5.To conduct any other business properly brought before the meeting.
|
| 2017-03-31 |
股东大会：
将于2017-05-12召开股东大会
会议内容 ▼▲
- 1.To elect the nominees for director, Charles J. Link, Jr., M.D., Paolo Pucci and Thomas A. Raffin, nominated by our Board of Directors, to serve until the 2020 Annual Meeting of Stockholders.
2.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
3.To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017.
4.To conduct any other business properly brought before the meeting.
|
| 2016-04-06 |
股东大会：
将于2016-05-20召开股东大会
会议内容 ▼▲
- 1. To elect the nominees for director, Paul R. Edick, Joseph B. Saluri and Nicholas N. Vahanian, M.D., nominated by our Board of Directors, to serve until the 2019 Annual Meeting of Stockholders.
2. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
3. To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
4. To conduct any other business properly brought before the meeting.
|